Clinical Science (London, England : 1979)最新文献_第9页

Potential role of perivascular adipose tissue in modulating atherosclerosis. 血管周围脂肪组织在调节动脉粥样硬化中的潜在作用。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2020-01-17 DOI: 10.1042/CS20190577

Samah Ahmadieh, Ha Won Kim, Neal L Weintraub

{"title":"Potential role of perivascular adipose tissue in modulating atherosclerosis.","authors":"Samah Ahmadieh, Ha Won Kim, Neal L Weintraub","doi":"10.1042/CS20190577","DOIUrl":"https://doi.org/10.1042/CS20190577","url":null,"abstract":"Perivascular adipose tissue (PVAT) directly juxtaposes the vascular adventitia and contains a distinct mixture of mature adipocytes, preadipocytes, stem cells, and inflammatory cells that communicate via adipocytokines and other signaling mediators with the nearby vessel wall to regulate vascular function. Cross-talk between perivascular adipocytes and the cells in the blood vessel wall is vital for normal vascular function and becomes perturbed in diseases such as atherosclerosis. Perivascular adipocytes surrounding coronary arteries may be primed to promote inflammation and angiogenesis, and PVAT phenotypic changes occurring in the setting of obesity, hyperlipidemia etc., are fundamentally important in determining a pathogenic versus protective role of PVAT in vascular disease. Recent discoveries have advanced our understanding of the role of perivascular adipocytes in modulating vascular function. However, their impact on cardiovascular disease (CVD), particularly in humans, is yet to be fully elucidated. This review will highlight the complex mechanisms whereby PVAT regulates atherosclerosis, with an emphasis on clinical implications of PVAT and emerging strategies for evaluation and treatment of CVD based on PVAT biology.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"3-13"},"PeriodicalIF":6.0,"publicationDate":"2020-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/90/b5/cs-134-cs20190577.PMC6944729.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37509380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 33

Depletion of CD11c+ cell attenuates progression of abdominal aortic aneurysm. CD11c+细胞的缺失减缓了腹主动脉瘤的进展。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2020-01-17 DOI: 10.1042/CS20191083

Keisuke Okuno, Stephanie Cicalese, Satoru Eguchi

引用次数: 1

Protective role of peroxiredoxin-4 in heart failure. 过氧化物还毒素-4在心力衰竭中的保护作用。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2020-01-17 DOI: 10.1042/CS20191072

Naseer Ahmed, Masooma Naseem, Javeria Farooq

引用次数: 1

A protective role of renalase in diabetic nephropathy. 肾化酶在糖尿病肾病中的保护作用。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2020-01-17 DOI: 10.1042/CS20190995

Jianyong Yin, Xuanchen Liu, Ting Zhao, Rulian Liang, Rui Wu, Fangfei Zhang, Yiwei Kong, Limei Liu, Tao Xing, Niansong Wang, Qing Zhao, Feng Wang

{"title":"A protective role of renalase in diabetic nephropathy.","authors":"Jianyong Yin, Xuanchen Liu, Ting Zhao, Rulian Liang, Rui Wu, Fangfei Zhang, Yiwei Kong, Limei Liu, Tao Xing, Niansong Wang, Qing Zhao, Feng Wang","doi":"10.1042/CS20190995","DOIUrl":"https://doi.org/10.1042/CS20190995","url":null,"abstract":"Renalase, a recently discovered secreted flavoprotein, exerts anti-apoptotic and anti-inflammatory effects against renal injury in acute and chronic animal models. However, whether Renalase elicits similar effects in the development of diabetic nephropathy (DN) remains unclear. The studies presented here tested the hypothesis that Renalase may play a key role in the development of DN and may have therapeutic potential for DN. Renalase expression was measured in human kidney biopsies with DN and in kidneys of db/db mice. The role of Renalase in the development of DN was examined using a genetically engineered mouse model: Renalase knockout mice with db/db background. The renoprotective effects of Renalase in DN was evaluated in db/db mice with Renalase overexpression. In addition, the effects of Renalase on high glucose-induced mesangial cells were investigated. Renalase was down-regulated in human diabetic kidneys and in kidneys of db/db mice compared with healthy controls or db/m mice. Renalase homozygous knockout increased arterial blood pressure significantly in db/db mice while heterozygous knockout did not. Renalase heterozygous knockout resulted in elevated albuminuria and increased renal mesangial expansion in db/db mice. Mesangial hypertrophy, renal inflammation, and pathological injury in diabetic Renalase heterozygous knockout mice were significantly exacerbated compared with wild-type littermates. Moreover, Renalase overexpression significantly ameliorated renal injury in db/db mice. Mechanistically, Renalase attenuated high glucose-induced profibrotic gene expression and p21 expression through inhibiting extracellular regulated protein kinases (ERK1/2). The present study suggested that Renalase protected against the progression of DN and might be a novel therapeutic target for the treatment of DN.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"75-85"},"PeriodicalIF":6.0,"publicationDate":"2020-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37510499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Correction: MIB1 mutations reduce notch signaling activation and contribute to congenital heart disease. 更正:MIB1突变减少notch信号激活并导致先天性心脏病。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2020-01-17 DOI: 10.1042/CS-20180732_COR

引用次数: 0

Overexpression of the aryl hydrocarbon receptor nuclear translocator partially rescues fetoplacental angiogenesis in severe fetal growth restriction. 芳烃受体核转运子的过度表达部分地挽救了严重胎儿生长受限的胎儿胎盘血管生成。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2019-06-20 Print Date: 2019-06-28 DOI: 10.1042/CS20190381

Shuhan Ji, Hong Xin, Emily J Su

{"title":"Overexpression of the aryl hydrocarbon receptor nuclear translocator partially rescues fetoplacental angiogenesis in severe fetal growth restriction.","authors":"Shuhan Ji, Hong Xin, Emily J Su","doi":"10.1042/CS20190381","DOIUrl":"https://doi.org/10.1042/CS20190381","url":null,"abstract":"Pregnancies complicated by severe fetal growth restriction with abnormal umbilical artery Doppler velocimetry (FGRadv) are at substantial risk for adverse perinatal and long-term outcomes. Impaired angiogenesis of the placental vasculature in these pregnancies results in a sparse, poorly branched vascular tree, which structurally contributes to the abnormally elevated fetoplacental vascular resistance that is clinically manifested by absent or reversed umbilical artery Doppler indices. Previous studies have shown that aryl hydrocarbon receptor nuclear translocator (ARNT) is a key mediator of proper placental angiogenesis, and within placental endothelial cells (ECs) from human FGRadv pregnancies, low expression of ARNT leads to decreased vascular endothelial growth factor A (VEGFA) expression and deficient tube formation. Thus, the aim of the present study was to determine the effect of VEGFA administration or ARNT overexpression on angiogenic potential of FGRadv ECs. ECs were isolated and cultured from FGRadv or gestational age-matched control placentas and subjected to either vehicle vs VEGFA treatment or transduction with adenoviral-CMV (ad-CMV) vs adenoviral-ARNT (ad-ARNT) constructs. They were then assessed via wound scratch and tube formation assays. We found that VEGFA administration nominally improved FGRadv EC migration (P<0.01) and tube formation (P<0.05). ARNT overexpression led to significantly enhanced ARNT expression in FGRadv ECs (P<0.01), to a level similar to control ECs. Despite this, FGRadv EC migration (P<0.05) and tube formation (P<0.05) were still only partially rescued. This suggests that although ARNT does play a role in fetoplacental EC migration, other factors in addition to ARNT are likely also important in placental angiogenesis.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"1353-1365"},"PeriodicalIF":6.0,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1042/CS20190381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37320647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease. 长链非编码RNA:糖尿病和糖尿病肾病的新参与者。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2019-06-20 Print Date: 2019-06-28 DOI: 10.1042/CS20190372

Jia Guo, Zhangsuo Liu, Rujun Gong

{"title":"Long noncoding RNA: an emerging player in diabetes and diabetic kidney disease.","authors":"Jia Guo, Zhangsuo Liu, Rujun Gong","doi":"10.1042/CS20190372","DOIUrl":"https://doi.org/10.1042/CS20190372","url":null,"abstract":"Diabetic kidney disease (DKD) is among the most common complications of diabetes mellitus (DM), and remains the leading cause of end-stage renal diseases (ESRDs) in developed countries, with no definitive therapy yet available. It is imperative to decipher the exact mechanisms underlying DKD and identify novel therapeutic targets. Burgeoning evidence indicates that long non-coding RNAs (lncRNAs) are essential for diverse biological processes. However, their roles and the mechanisms of action remain to be defined in disease conditions like diabetes and DKD. The pathogenesis of DKD is twofold, so is the principle of treatments. As the underlying disease, diabetes per se is the root cause of DKD and thus a primary focus of therapy. Meanwhile, aberrant molecular signaling in kidney parenchymal cells and inflammatory cells may directly contribute to DKD. Evidence suggests that a number of lncRNAs are centrally involved in development and progression of DKD either via direct pathogenic roles or as indirect mediators of some nephropathic pathways, like TGF-β1, NF-κB, STAT3 and GSK-3β signaling. Some lncRNAs are thus likely to serve as biomarkers for early diagnosis or prognosis of DKD or as therapeutic targets for slowing progression or even inducing regression of established DKD. Here, we elaborated the latest evidence in support of lncRNAs as a key player in DKD. In an attempt to strengthen our understanding of the pathogenesis of DKD, and to envisage novel therapeutic strategies based on targeting lncRNAs, we also delineated the potential mechanisms of action as well as the efficacy of targeting lncRNA in preclinical models of DKD.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"1321-1339"},"PeriodicalIF":6.0,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1042/CS20190372","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37351048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 79

Endothelin receptor antagonism during preeclampsia: a matter of timing? 子痫前期内皮素受体拮抗剂:时间问题?

IF 6

Clinical Science (London, England : 1979) Pub Date : 2019-06-20 Print Date: 2019-06-28 DOI: 10.1042/CS20190464

Emilie Hitzerd, Rugina I Neuman, Katrina M Mirabito Colafella, Irwin K M Reiss, Anton H van den Meiracker, A H Jan Danser, Willy Visser, Jorie Versmissen, Langeza Saleh

{"title":"Endothelin receptor antagonism during preeclampsia: a matter of timing?","authors":"Emilie Hitzerd, Rugina I Neuman, Katrina M Mirabito Colafella, Irwin K M Reiss, Anton H van den Meiracker, A H Jan Danser, Willy Visser, Jorie Versmissen, Langeza Saleh","doi":"10.1042/CS20190464","DOIUrl":"https://doi.org/10.1042/CS20190464","url":null,"abstract":"Preeclampsia (PE) is a pregnancy complication, featuring elevated blood pressure and proteinuria, with no appropriate treatment. Activation of the endothelin system has emerged as an important pathway in PE pathophysiology based on experimental PE models where endothelin receptor antagonists (ERAs) prevented or attenuated hypertension and proteinuria. Hence, ERAs have been suggested as potential therapy for PE. However, developmental toxicity studies in animals have shown severe teratogenic effects of ERAs, particularly craniofacial malformations. Nonetheless, sporadic cases of pregnancy in women using ERAs to treat pulmonary hypertension have been described. In this review we give an overview of cases describing ERA use in pregnancy and critically address their possible teratogenic effects. A systematic search in literature yielded 18 articles describing 39 cases with ERA exposure during human pregnancy. In most cases there was only exposure in the first trimester, but exposure later or throughout pregnancy was reported in five cases. Elective termination of pregnancy was performed in 12 pregnancies (31%), two ended in a spontaneous miscarriage (5%) and no fetal congenital abnormalities have been described in the remaining cases. These preliminary findings support the idea that ERA treatment for severe, early onset PE might be an option if applied later in pregnancy, when organogenesis is completed to avoid teratogenic risks. However, third trimester toxicology studies are warranted to evaluate drug safety. Subsequently, it remains to be established whether ERA treatment is effective for alleviating maternal symptoms, as demonstrated in preclinical PE models, allowing pregnancy prolongation without leading to adverse neonatal outcomes.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"1341-1352"},"PeriodicalIF":6.0,"publicationDate":"2019-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1042/CS20190464","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37351049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

Revisiting hypoxia therapies for tuberculosis. 重新审视肺结核的缺氧治疗。

IF 6

Clinical Science (London, England : 1979) Pub Date : 2019-06-17 Print Date: 2019-06-28 DOI: 10.1042/CS20190415

Stefan H Oehlers

引用次数: 11

Association of functional variant in GDF1 promoter with risk of congenital heart disease and its regulation by Nkx2.5. GDF1启动子功能变异与先天性心脏病风险的关系及Nkx2.5的调控作用

IF 6

Clinical Science (London, England : 1979) Pub Date : 2019-06-17 Print Date: 2019-06-28 DOI: 10.1042/CS20181024

Xiaobo Gao, Panpan Zheng, Liping Yang, Haiyan Luo, Chen Zhang, Yongqiang Qiu, Guoying Huang, Wei Sheng, Xu Ma, Cailing Lu

{"title":"Association of functional variant in GDF1 promoter with risk of congenital heart disease and its regulation by Nkx2.5.","authors":"Xiaobo Gao, Panpan Zheng, Liping Yang, Haiyan Luo, Chen Zhang, Yongqiang Qiu, Guoying Huang, Wei Sheng, Xu Ma, Cailing Lu","doi":"10.1042/CS20181024","DOIUrl":"https://doi.org/10.1042/CS20181024","url":null,"abstract":"GDF1 plays an important role in left-right patterning and genetic mutations in the coding region of GDF1 are associated with congenital heart disease (CHD). However, the genetic variation in the promoter of GDF1 with sporadic CHD and its expression regulation is little known. The association of the genetic variation in GDF1 promoter with CHD was examined in two case-control studies, including 1084 cases and 1198 controls in the first study and 582 cases and 615 controls in the second study. We identified one single nucleotide polymorphism (SNP) rs181317402 and two novel genetic mutations located in the promoter region of GDF1. Analysis of combined samples revealed a significant association in genotype and allele frequencies of rs181317402 T/G polymorphism between CHD cases in overall or ventricular septal defects or Tetralogy of Fallot and the control group. rs181317402 allele G polymorphism was significantly associated with a decreased risk of CHD. Furthermore, luciferase assay, chromatin immunoprecipitation and DNA pulldown assay indicated that Nkx2.5 transactivated the expression of GDF1 by binding to the promoter of GDF1. Luciferase activity assay showed that rs181317402 allele G significantly increased the basal and Nkx2.5-mediated activity of GDF1 promoter, while the two genetic mutations had the opposite effect. rs181317402 TG genotype was associated with significantly increased mRNA level of GDF1 compared with TT genotype in 18 CHD individuals. Our results demonstrate for the first time that Nkx2.5 acts upstream of GDF1 and the genetic variants in GDF1 promoter may confer genetic susceptibility to sporadic CHD potentially by altering its expression.","PeriodicalId":519494,"journal":{"name":"Clinical Science (London, England : 1979)","volume":" ","pages":"1281-1295"},"PeriodicalIF":6.0,"publicationDate":"2019-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1042/CS20181024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37307082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7